Burger Henry G
Prince Henry's Institute of Medical Research and Jean Hailes Foundation for Women's Health, Clayton, Victoria, Australia.
Aust N Z J Obstet Gynaecol. 2006 Apr;46(2):84-91. doi: 10.1111/j.1479-828X.2006.00533.x.
The announcement in July 2002 in the media of the results of the combined continuous hormone treatment arm of the Women's Health Initiative (WHI) had a profound effect on perceptions about hormone therapy among the lay public and the medical profession. Careful scrutiny of the announcement and the subsequent publications leads to the conclusion that the widespread fear of hormone therapy that was generated was not supported by the facts. WHI was not designed to be, nor can it be, interpreted as a randomised controlled trial of menopausal hormone therapy--rather, it was a trial of chronic disease prevention, particularly aimed at the possible cardiovascular benefits of a specific combination hormone therapy in postmenopausal women. The results, which were consistent with existing data, did not and do not warrant any major change in the previously established guidelines for the use of hormone therapy. Tibolone has emerged as an alternative treatment for menopausal symptoms, but its long-term benefits and risks have yet to be documented.
2002年7月媒体公布的妇女健康倡议（WHI）联合连续激素治疗组的结果，对普通公众和医学界对激素疗法的认知产生了深远影响。对该公告及后续出版物的仔细审查得出的结论是，由此引发的对激素疗法的广泛恐惧并无事实依据。WHI并非设计用于，也不能被解释为绝经激素疗法的随机对照试验——相反，它是一项慢性病预防试验，尤其旨在研究特定联合激素疗法对绝经后女性可能的心血管益处。这些结果与现有数据一致，过去和现在都不支持对先前制定的激素疗法使用指南进行任何重大更改。替勃龙已成为治疗绝经症状的替代疗法，但其长期益处和风险尚未得到证实。
